Contribution of Proteomics in Transplantation: Identification of Injury and Rejection Markers

Abstract

Solid organ transplantation saves thousands of lives suffering from end-stage diseases. Although early transplants experienced acute organ injury, medical breakthroughs, such as tissue typing, and use of immunosuppressive agents have considerably improved graft survival. However, the overall incidence of allograft injury and chronic rejection remains high. Often the clinical manifestations of organ injury or rejection are nonspecific and late. Current requirement for successful organ transplantation is the identification of reliable, accurate, disease-specific, noninvasive methods for the early diagnosis of graft injury or rejection. Development of noninvasive techniques is important to allow routine follow-ups without the discomfort and risks associated with a graft biopsy. Multiple biofluids have been successfully tested for the presence of potential proteomic biomarkers; these include serum, plasma, urine, and whole blood. Kidney transplant research has provided significant evidence to the potential of proteomics-based biomarkers for acute and chronic kidney rejection, delayed graft function, early detection of declining allograft health. Multiple proteins have been implicated as biomarkers; however, recent observations implicate the use of similar canonical pathways and biofunctions associated with graft injury/rejection with altered proteins as potential biomarkers. Unfortunately, the current biomarker studies lack high sensitivity and specificity, adding to the complexity of their utility in the clinical space. In this review, we first describe the high-throughput proteomics technologies and then discuss the outcomes of proteomics profiling studies in the transplantation of several organs. Existing literature provides hope that novel biomarkers will emerge from ongoing efforts and guide physicians in delivering specific therapies to prolong graft survival.

What Is Hot and New in Basic and Translational Science in Liver Transplantation in 2023? Report of the Basic and Translational Research Committee of the International Liver Transplantation Society

“…About the lifelong consequences of IS, Zubair et al 49 used RT-qPCR to analyze urine samples from patients under tacrolimus based immunosuppressant regimen and proposed a 7-gene signature by analyzing urine samples (7 genes) that was able to distinguish patients with nephrotoxicity related to calcineurin inhibitors with an ROC curve of 0.85. Wang et al 50 presented an interesting study using a combination of in vitro and airway organoid models to test the effect of different immunosuppressants on the replication of varying coronavirus variants.…”

High-throughput CRISPR technology: a novel horizon for solid organ transplantation

“…Enhancing the effector function of therapeutic cells with CRISPR/Cas9 based genome editing, providing one potential solution (20)(21)(22). However, current studies have identified limited genetic targets that can effectively regulate the immune cells in transplantation (23). Exploring new intervention targets for immunosuppressant and cellular immunomodulatory therapies is urgent.…”

Fecal and Urinary Adipokines as Disease Biomarkers

“…The best treatment for kidney failure is organ transplantation. However, the incidence of organ rejection is high, and non-invasive biomarkers for early diagnosis of rejection are required [ 221 ]. Given the marker potential of IL-6 levels in the urine as a read-out for kidney function (see above Section 2.6.3 , Section 2.6.4 and Section 2.6.5 ), IL-6 concentrations were monitored over the first 30 postoperative days in 40 patients receiving renal transplants.…”